|
Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer Clinical Trials Resources presented on Clinical Trials Search is not meant to be a substitute for proven health advice, calls or treatment with a real medical. We aren't mDs. Always consult your doctor on Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer Clinical research trials and Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer healthcare trials take place in a lot of of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectiveness of new does drugs. The function of the studies / projects is to figure out specific human medical questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to find cures for all varieties of conditions, like Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer. Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer Clinical Trials and other clinical trials allow volunteers to access health treatment options before they are available to the masses. Many times the subjects receive professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer clinical trial. Human subjects often obtain the finest healthcare possible for their Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer condition. Hazards are a reality, nevertheless, and might include additional or frequent dr. calls, health hazards (potentially life-jeopardizing), and/or the treatment being uneffective. Trials are federally regulated with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "F" Clinical Trials Conditions > Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer  Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer
Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer
For Condition: stage 3A non-small cell lung cancer,stage 2 non-small cell lung cancer,stage 3B non-small cell lung cancer
Status: Not yet recruiting
Sponsor(s): American College of Radiology Imaging Network , National Cancer Institute (NCI),Radiation Therapy Oncology Group
Synopsis: RATIONALE: Imaging procedures such as fludeoxyglucose F18positron emission tomography (18FDG-PET) may improve the ability to detect disease progression and help doctors predict a patient's response to treatment and plan more effective treatment. PURPOSE: Diagnostic trial to study the effectiveness of 18FDG-PET imaging in detecting disease progression and determining response to treatment in patients undergoing chemoradiotherapy for locally advancednon-small cell lung cancer.
Details: OBJECTIVES: Primary - Determine whether peak standardized uptake value (SUV) for fludeoxyglucose F 18 positron emission tomography shortly after definitive chemoradiotherapy is predictive of long-term survival of patients with inoperable stage IIB or III non-small cell lung cancer. Secondary - Determine whether post-treatment imaging using this technique is predictive of local disease control in these patients. - Determine whether pre-treatment imaging using this technique is predictive of long-term survival and local disease control in these patients. - Correlate, if possible, Ki-67 expression with overall survival of patients assessed with this imaging technique. OUTLINE: This is a diagnostic, multicenter study. Before starting chemoradiotherapy, patients undergo baseline whole-body positron emission tomography (PET) imaging. Patients receive fludeoxyglucose F 18 (^18FDG) IV followed 45-60 minutes later by PET imaging. Patients then receive concurrent definitive radiotherapy and chemotherapy. Patients enrolled in other treatment-oriented clinical trials receive therapy as per that trial. Other patients receive standard thoracic radiotherapy (dose ≥ 60 Gy) and standard chemotherapy comprising a platin (cisplatin or carboplatin) and a second non-platin, non-gemcitabine drug (etoposide, vinblastine, vinorelbine, paclitaxel, or docetaxel). Approximately 14 weeks after completion of chemoradiotherapy and adjuvant chemotherapy (if given), patients undergo post-treatment ^18FDG-PET imaging. Patients are followed every 3 months for 2 years and then every 6 months for 1-3 years. PROJECTED ACCRUAL: A total of 250 patients (including at least 75 with stage IIB/IIIA disease and at least 75 with stage IIIB disease) will be accrued for this study within 2 years.
Eligibility:
Study Type: Interventional, Diagnostic
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed non-small cell lung cancer (NSCLC) - Clinical stage IIB or III disease - No small cell carcinoma - No stage IV disease* - No diffuse bronchoalveolar subtype - No planned definitive surgical resection NOTE: *Patients with evidence of stage IV disease by positron emission tomography are eligible if the evidence cannot be confirmed by other means AND the physician still plans to proceed with definitive chemoradiation - Planning treatment with definitive chemoradiotherapy - May be treated on another Radiation Therapy Oncology Group protocol (except phase I studies) OR with conventional concurrent NSCLC chemoradiotherapy - Radiotherapy 60 Gy AND chemotherapy to include concurrent platinum-based therapy - No brain metastases by head CT scan or MRI PATIENT CHARACTERISTICS: Age - 18 and over Performance status - Zubrod 0-1 Life expectancy - Not specified Hematopoietic - Not specified Hepatic - Not specified Renal - Not specified Other - Medically suitable for early concurrent chemoradiotherapy (radiotherapy dose 60 Gy) - Able to tolerate positron emission tomography imaging - No poorly controlled diabetes (defined as fasting glucose level > 200 mg/dL) - No other malignancy within the past 3 years except basal cell or squamous cell skin cancer or carcinoma in situ - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception during and for 3 months after study participation PRIOR CONCURRENT THERAPY: Biologic therapy - No anticipated use of adjuvant biologic therapy beyond 14 weeks after the completion of radiotherapy Chemotherapy - See Disease Characteristics - No anticipated use of adjuvant chemotherapy beyond 14 weeks after the completion of radiotherapy Endocrine therapy - Not specified Radiotherapy - See Disease Characteristics - No prior thoracic radiotherapy - No concurrent intensity-modulated radiotherapy Surgery - See Disease Characteristics Other - No concurrent participation in a phase I study using investigational drug therapy
Total Enrollment:
Location and Contact Information:
Overall Study Official:
MitchellMachtay, Study Chair, Kimmel Cancer Center (KCC)
Additional Information:
Study ID Numbers: CDR0000362061; ACRIN-6668,RTOG-0235
Study Start Date:
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00083083
Other Stage 3b Non-Small Cell Lung Cancer Studies:
1. Radiation Therapy Using 3-Dimensional Treatment Planning in Patients With Non-small Cell Lung Cancer
2. Radiation Therapy in Preventing CNS Metastases in Patients With Non-Small Cell Lung Cancer
3. Chemotherapy and Radiation Therapy With or Without Epoetin alfa in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer
4. Carboxyamidotriazole in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer
5. Combination Chemotherapy Plus Radiation Therapy With or Without Gefitinib in Treating Patients With Unresectable Stage III Non-Small Cell Lung Cancer
Related Studies:
Other stage 3B non-small cell lung cancer Clinical Trials
Other Clinical Trials
Other Clinical Trials
Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer
|
|
|
|
|
|
|
|
